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journa l homepage: www.europea nurology.comIn the midst of the COVID-19 pandemic, many surgical
subspecialties, including urology, have dealt with the
resulting emergency by suspending elective services and
delaying many time-sensitive surgeries. Hematuria work-
ups and bladder cancer (BCa) staging have been consid-
ered a priority because of the potential aggressive
behavior of this disease. Evidence suggests that cancer
patients are at higher risk of death from COVID-19
[1]. Thus, minimizing the potential exposure of this group
by reducing hospital visits and admissions, postponing
low-risk surgeries, and delaying or reconsidering intra-
venous therapies has to be factored into the risk/benefit
discussion for BCa patients.
The Vesical Imaging-Reporting and Data System (VI-
RADS) [2] may offer a reliable initial diagnostic tool to aid in
risk stratification to identify patients who would benefit
from immediate intervention versus a delay in management
during this crisis. Three specific scenarios warrant special
attention: (1) initial diagnostic work-up for gross hematu-
ria; (2) selection of patients with high-risk non–muscle-
invasive BCa for restaging transurethral resection; and (3)
assessment for neoadjuvant regimen administration for
locally advanced disease.
According to a recent meta-analysis [3], a VI-RADS
criterion of 3 before primary transurethral resection of
bladder tumor (TURBT) had cumulative diagnostic accuracy
of 0.94 (95% confidence interval [CI] 0.91–0.95) in identify-
ing muscle-invasive BCa on pathology. In addition, the VI-
RADS score is designed to provide locoregional staging and
to predict the likelihood of organ-confined versus locally
invasive disease. Consequently, applying VI-RADS at the
time of presentation with gross hematuria may aid
urologists in minimizing elective procedures and obtaining
a radiation-free the evaluation of both T and N staging from
a single examination, while providing a prognostic criterionPlease cite this article in press as: Panebianco V, et al. VI-RADS S
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waiting lists (Fig. 1A).
This ability to differentiate non–muscle-invasive from
muscle invasive BCa was used to predict BCa upstaging at
repeat TURBT in a recent prospective series (area under the
receiver operating characteristic curve 0.93, 95% CI 0.87–
0.97) [4] and therefore VI-RADS has been proposed for
avoiding repeat TURBT according to the European Associa-
tion of Urology guidelines. This may be particularly useful in
cases lacking muscularis propria in the specimen or in the
setting of a unifocal, small, high-grade Ta/T1 tumor, for
which a preoperative VI-RADS score of 1–2 may indicate a
low likelihood of tumor understaging and therefore
patients may be quickly directed to appropriate adjuvant
intravesical therapy for follow-up. This relatively safe
approach might minimize potential exposure to COVID-
19 infection by avoiding a second hospital admission for a
surgical procedure that is not devoid of possible complica-
tions (Fig. 1B).
Finally, a growing body of recommendations is suggest-
ing careful selection of radical cystectomy (RC) candidates
for neoadjuvant systemic therapy [5]. The final treatment
decision will need to take into account several factors,
including the evolution of the pandemic, local health
system capacity, and the overall performance status of the
patient. Detection of a VI-RADS score of 5 might aid in
identifying cases with high-volume disease and advanced
stage who could benefit most from early neoadjuvant
therapy. Conversely, patients with a VI-RADS score of <5
could proceed directly to RC and avoid the risk of exposure
associated with neoadjuvant regimens (Fig. 1C).
In conclusion, we want to underline that this document
is meant not as an alternative to available guidelines, but
rather as an expert opinion on possible alternatives and
decision aids in the treatment of BCa during a pandemic.coring Criteria for Alternative Risk-adapted Strategies in the
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Figure 1 – Possible alternatives in the diagnostic and therapeutic management of bladder cancer during the COVID-19 pandemic. (A) Work-up for gross
hematuria. * Elective gross hematuria work-up (ie, not requiring emergency interventions or immediate hospitalization). (B) Work-up for non–muscle-
invasive bladder cancer (NMIBC) candidate for Re-TURBT. * Except for Ta low-grade/G1 tumors and primary carcinoma in situ. (C) Work-up for muscle-
invasive bladder cancer (MIBC). * Except for Ta low-grade/G1 tumors and primary carcinoma in situ. CT = computed tomography; MRI = magnetic
resonance imaging; VI-RADS = Vesical Imaging-Reporting and Data System; TURBT = transurethral resection of bladder tumor; EUA = European
Association of Urology; BCG = bacillus Calmette-Guérin; Re-TURBT = repeat TURBT; RC = radical cystectomy; NAC = neoadjuvant systemic chemotherapy;
HG = high grade; AACCI = age-adjusted Charlson comorbidity index.
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